Modeling the effects of treating diabetic wounds with engineered skin substitutes

Wound Repair and Regeneration

Volumn 15, Issue 4, 2007, Pages 556-565

  Waugh, Helen V ^a   Sherratt, Jonathan A ^a  

^a HERIOT WATT UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECAPLERMIN; COLLAGEN; HYALURONIC ACID; PLATELET DERIVED GROWTH FACTOR;

ARTICLE; DIABETIC WOUND; FIBROBLAST; MATHEMATICAL MODEL; PRIORITY JOURNAL; TISSUE ENGINEERING; WOUND; WOUND CLOSURE; WOUND HEALING;

COATED MATERIALS, BIOCOMPATIBLE; COLLAGEN; DIABETES MELLITUS; HUMANS; HYALURONIC ACID; MODELS, BIOLOGICAL; MONOCYTES; SKIN, ARTIFICIAL; TISSUE ENGINEERING; WOUND HEALING;

EID: 34447635744     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/j.1524-475X.2007.00270.x     Document Type: Article

References (49)

1. Marston WA. Dermagraft™, a bioengineered human dermal equivalent for the treatment of the chronic nonhealing diabetic foot ulcer. Expert Rev Med Devices 2004 1 : 21 31.
2. Streit M, Braathen LR. Apligraf™ - a living human skin equivalent for the treatment of chronic wounds. Int J Artificial Organs 2000 23 : 831 3.
3. Leaper D, Paggi B, Compton GA, Orsted H, Teot LM, Ockenfels HM. Growth factors and interactive dressings in wound repair. EWMA J 2002 2 : 17 23.
4. Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower-extremity diabetic ulcer: a combined analysis of four randomised studies. Wound Repair Regen 1999 7 : 335 56.
5. Loots A. Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J Invest Dermatol 1998 111 : 850 7.
6. Zykova SN. Altered cytokine and nitric oxide secretion in vitro by macrophages from diabetic type II-like db/db mice. Diabetes 2000 49 : 1451 8.
7. Robson MC, Steed DL, Franz MG. Wound healing: biologic features and approaches to maximize healing trajectories. Curr Problems Surg 2001 38 : 65 140.
8. Clark RAF. The molecular and cellular biology of wound repair. 2nd ed. New York: Plenum Press, 1996.
9. Cobbold CA, Sherratt JA. Mathematical modelling of nitric oxide activity in wound healing can explain keloid and hypertrophic scarring. J Theoret Biol 2000 204 : 257 88.
10. Hehenberger K, Heilborn JD, Brismar K, Hansson A. Inhibited proliferation of fibroblasts derived from chronic diabetic wounds and normal fibroblasts treated with high glucose is associated with increased formation of l-lactate. Wound Repair Regen 1998 6 : 135 41.
11. Loots MAM, Lamme EN, Mekkes JR, Bos JD, Middelkoop E. Cultured fibroblasts from chronic diabetic wounds on the lower extremity (non-insulin-dependent diabetes mellitus) show disturbed proliferation. Arch Dermatol Res 1999 291 : 93 9.
12. Waugh HV, Sherratt JA. Macrophage dynamics in diabetic wound healing. Bull Math Biol 2006 68 : 197 207.
13. Darby A, Bisucci T, Hewitson TD, MacLellan DG. Apoptosis is increased in a model of diabetes-impaired wound healing in genetically diabetic mice. Int J Biochem Cell Biol 1997 29 : 191 200.
14. Hascall VC, Laurent TC. Hyaluronan structure and physical properties web document. Available at :, 2000. Accessed 2005.
15. Ignotz RA, Massague J. Transforming growth factor-β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1985 261 : 4337 45.
16. Raghow R, Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH. Transforming growth factor-β increases steady state levels of type I procollagen and fibronectin messenger RNAs post-transcriptionally in cultured human dermal fibroblasts. J Clin Invest 1987 79 : 1285 8.
17. Roberts AN, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, Fauci AS. Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986 83 : 4167 71.
18. Lee KH. Tissue-engineered human living skin substitutes: development and clinical application. Yonsei Med J 2000 41 : 774 9.
19. Limova M. New therapeutic options for chronic wounds. Dermatol Clin 2002 20 : 357 63.
20. Schmid P. Immunohistologic characterisation of Graftskin (Apligraf™). Wounds: a compendium of clinical research and practice. 2000 12 (Suppl. A) : 4A 11A.
21. Naughton GK. From lab bench to market: critical issues in tissue engineering. Ann NY Acad Sci 2002 961 : 372 85.
22. Naughton GK, Mansbridge J, Gentzkow G. A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Arti Organs 1997 21 : 1203 10.
23. Mansbridge J, Lui K, Patch R, Symons K, Pinney E. Three-dimensional fibroblast culture implant for the treatment of diabetic foot ulcers: metabolic activity and therapeutic range. Tissue Eng 1998 4 : 403 14.
24. Mansbridge J, Lui K, Pinney E, Patch R, Ratcliffe A, Naughton GK. Growth factors secreted by fibroblasts: role in healing diabetic foot ulcers. Diabetes Obes Metabol 1999 1 : 265 70.
25. Marston WA, Hanft J, Norwood P, Pollak R, For the Dermagraft Diabetic Foot Ulcer Study Group. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers. Diabetes Care 2003 26 : 1701 5.
26. Curran MP, Plosker GL. Bilayered bioengineered skin substitute (Apligraf™): a review of its use in the treatment of venous leg ulcers and diabetic foot ulcers. BioDrugs 2002 16 : 439 55.
27. Organogenesis Apligraf™ prescribing information, 2003.
28. Margolis DJ, Crombleholme T, Herlyn M. Clinical protocol: phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound Repair Regen 2000 8 : 480 93.
29. Embil JM, Papp K, Tousignant J, Smiell JM, Wong B, Lau CY. The Canadian becaplermin study group. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy. Wound Repair Regen 2000 8 : 162 8.
30. Falanga V. The chronic wound: impaired healing and solutions in the context of wound bed preparation. Blood Cells Mol Dis 2004 32 : 88 94.
31. Baker EA, El-Gaddal S, Aitken DG, Leaper DJ. Growth factor profiles in intraperitoneal drainage fluid following colorectal surgery: relationship to wound healing and surgery. Wound Repair Regen 2003 11 : 261 7.
32. Singer AJ, Clark RAF. Cutaneous wound healing. N Engl J Med 1999 341 : 738 46.
33. Sheehan KM, DeLott LB, Day SM, DeHeer DH. Hyalgan has a dose-dependent differential effect on macrophage proliferation and cell death. J Othorp Res 2003 21 : 744 51.
34. Bellingan GJ, Caldwell H, Howie SEM, Branesfield I, Haslett C. In vivo fate of the inflammatory macrophage during resolution of inflammation: inflammatory macrophages do not die locally, but emigrate to the draining lymph nodes. J Immunol 1996 157 : 2577 85.
35. Kemp P, Bell E, Kagan DT, Mason V, Cavallero J. Preparation of tissue equivalents by contraction of a collagen gel layered on a collagen gel. Patent document US 1996; 5:536,656.
36. Abatangelo G, Martelli M, Vecchia P. Healing of hyaluronic acid-enriched wounds: histological observations. J Surg Res 1983 35 : 410 6.
37. Naughton GK, Naughton BA. Three-dimensional cell and tissue culture system. Patent Document US 1990; 4:963,489.
38. Naughton GK, Naughton BA. Three-dimensional skin culture system. Patent document US 1993; 5:266,480.
39. Facchiano A, De Marchis F, Turchetti E, Facchiano F, Guglielmi M, Denaro A, Palumbo R, Scoccianti M, Capogrossi MC. The chemotactic and mitogenic effects of platelet-derived growth factor-BB on rat aorta smooth muscle cells are inhibited by basic fibroblast growth factor. J Cell Sci 2000 113 : 2855 63.
40. Grotendorst GR, Martin GR, Pencev D, Sodek J, Harvey AK. Stimulation of granulation tissue formation by platelet-derived growth factor in normal and diabetic rats. J Clin Invest 1985 76 : 2323 9.
41. Burke B, Lewis CE, editors. The macrophage. 2nd ed. Oxford, UK: Oxford University Press, 2002.
42. Miyasaki K. Chapter 5 - Monocytes in basic immunology course notes (web document), UCLA, 2002.
43. Munoz-Alicea R, Negron-Marrero P, Marcano-Velazquez M. A mathematical model for macrophage, T-cell and mycobacterium tuberculosis actions. Technical report. Humacao : University of Puerto Rico, 1999.
44. Mast TD. Simulation of ultrasonic pulse propagation through the abdominal wall. J Acoustical Soc Am 1997 102 (Part 1) : 1177 90.
45. Huang M, Sharma S, Zhu LX, Keane MP, Luo J, Zhang L, Burdick MD, Lin YQ, Dohadwala M, Gardner B, Batra RK, Strieter RM, Dubinett SM. IL-7 inhibits fibroblast TGF-β production and signalling in pulmonary fibrosis. J Clin Invest 2002 109 : 931 7.
46. Badgett A, Bonner JC, Brody AR. Interferon-gamma modulates lung macrophage production of PDGF-BB and fibroblast growth. J Lipid Mediators Cell Signal 1996 13 : 89 97.
47. Edward M, Micha D, Tammi RH. Tumour regulation of fibroblast hyaluronan: a mechanism to facilitate tumour growth and invasion. Carcinogenesis 2005 26 : 1215 23.
48. Bhandari B, Grandaliano G, Abboud HE. Platelet-derived growth factir (PDGF) BB homodimer regulates PDGF-A and PDGF-B chain gene transcription in human mesangial cells. Biochem J 1994 297 : 385 8.
49. Tammi R, Tammi M. Hyaluronan in the epidermis. Glycoscience web forum document. Available at :, 1998. Accessed 2005.